drugset / Trial / NCT00339196

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

NCT00339196

Phase 2 Completed 25 enrolled Assistance Publique - Hôpitaux de Paris
Non-randomizedSingle-groupOpen-labelTreatment

Summary

MULTICENTERS. Uncontrolled and open phase II study. Evaluation of the effectiveness of a treatment associating 5 Azacytidine,Valproic acid ,Retinoic Acid at subjects-reached of syndromes myelodysplasia and acute MYELOID leukaemia Hematological response at 6 months Uncontrolled prospective cohort.

Timeline

Start
2006-07
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified
Subject Isotretinoin Other / unclassified
Subject Valproic Acid Small molecule